PMID- 9819786
OWN - NLM
STAT- MEDLINE
DCOM- 19990129
LR  - 20190915
IS  - 0378-5122 (Print)
IS  - 0378-5122 (Linking)
VI  - 30
IP  - 1
DP  - 1998 Sep 20
TI  - Comparison between moexipril and atenolol in obese postmenopausal women with 
      hypertension.
PG  - 69-77
AB  - The present study investigated the effect of the new ACE-inhibitor moexipril 
      versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse 
      events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure 
      (SDBP) in obese postmenopausal women with hypertension (stage I and II). After a 
      4-week placebo run-in phase, 116 obese, postmenopausal women with primary 
      hypertension were randomised into two treatment groups receiving once daily 
      dosages of either moexipril 7.5 mg or atenolol 25 mg initially (mean age: 57 +/- 
      7 years in both groups; mean weight: 94 kg in the moexipril group and 89 kg in 
      the atenolol group, corresponding to a body mass index (BMI) of 35.2 kg/m2 and 
      34.1 kg/m2 in both groups, respectively). After 4 and 8 weeks, the dosages were 
      uptitrated to moexipril 15 mg, or if necessary to moexipril 15 
      mg/hydrochlorothiazide (HCTZ) 25 mg, or to atenolol 50 mg and atenolol 50 mg/HCTZ 
      25 mg, in patients whose blood pressure was not sufficiently controlled. At 
      endpoint, metabolic parameters (total cholesterol, triglycerides, LDL, HDL, 
      glucose, insulin) were not significantly altered in either treatment group. Most 
      frequent adverse events under monotherapy (moexipril/atenolol) were asthenia 
      (5.3/13.0%), headache (13.2/21.7%), cough (7.9/6.5%), pharyngitis (21.1/8.7%) and 
      peripheral oedema (5.3/13.0%). Overall at least one AE was reported in 66% of the 
      patients treated with moexipril and in 78% of those treated with atenolol. 
      Reduction of SSBP/SDBP at endpoint was 14.7 +/- 1.9/10.0 +/- 1.1 and 8.7 +/- 
      1.9/8.4 +/- 1.1 mmHg after treatment with moexipril and atenolol, respectively. 
      The results showed that moexipril and atenolol are equally effective in reducing 
      blood pressure without adversely affecting blood lipids and carbohydrate 
      metabolism.
FAU - Stimpel, M
AU  - Stimpel M
AD  - Schwarz Pharma AG, Department of Clinical Research, Monheim, Germany.
FAU - Koch, B
AU  - Koch B
FAU - Weber, M A
AU  - Weber MA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Isoquinolines)
RN  - 0 (Lipids)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 50VV3VW0TI (Atenolol)
RN  - WT87C52TJZ (moexipril)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Atenolol/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/blood/complications/*drug therapy
MH  - Isoquinolines/*therapeutic use
MH  - Lipids/blood
MH  - Middle Aged
MH  - Obesity/blood/*complications
MH  - *Postmenopause
MH  - *Tetrahydroisoquinolines
EDAT- 1998/11/20 00:00
MHDA- 1998/11/20 00:01
CRDT- 1998/11/20 00:00
PHST- 1998/11/20 00:00 [pubmed]
PHST- 1998/11/20 00:01 [medline]
PHST- 1998/11/20 00:00 [entrez]
AID - S0378512298000371 [pii]
AID - 10.1016/s0378-5122(98)00037-1 [doi]
PST - ppublish
SO  - Maturitas. 1998 Sep 20;30(1):69-77. doi: 10.1016/s0378-5122(98)00037-1.